Hanshow Showcases Retail Media and Store Intelligence at 2025 CGF Global Summit
19.6.2025 18:00:00 EEST | Business Wire | Press release
Hanshow, a global leader in digital retail solutions, underscored its leadership in AI, IoT, and Retail Media at the 2025 Global Summit of the Consumer Good Forum (CGF), held from June 11 to 13 at RAI Amsterdam. From an immersive ‘Future Store’ showcase in the I-Zone to moderating one of the Summit’s most anticipated panel discussions, Hanshow demonstrated how its integrated platform is driving the next wave of store transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619798164/en/
Inside the Future Store: Hanshow’s Real-Time Innovation at I-Zone
At Booth No.8 in the I-Zone, Hanshow presented an interactive showcase themed “Powering Your Future Store,” highlighting four core pillars of the future store: real-time pricing and shelf operations powered by ESLs; smart carts that enhance the shopping experience with autonomous navigation and seamless checkout; GenAI-enabled journeys offering contextual promotions and personalized assistance; and green technologies such as solar storage charging systems and in-store energy saving solutions.
Visitors explored how these technologies interoperate to elevate operational efficiency, enhance shopper experience, and advance sustainability. The showcase drew strong interest from retailers, tech leaders, and media, offering a vivid glimpse into how Hanshow is bridging digital and physical retail to deliver a unified, scalable transformation for digital and physical retail.
AI, IoT & RMNs: Driving the Next Wave of Retail Ecosystem Transformation
On June 12 in the Plenary Hall, a full house of industry attendees was eager to hear how AI, IoT, and Retail Media are reshaping the retail ecosystem. Philippe Brochard—Tech and Innovation Advisory Board Member at Hanshow and former Retail CEO, moderated the plenary panel “Redesigning Retail: AI, IoT and RMN – Empowering Tech-Driven Experiences and Sustainable Growth”, joined by:
- Klaus Smets, Vice President, Hanshow Europe
- Bas Komen, Director of Sales & Marketing for Retail Media, Albert Heijn
- Bart Zoetmulder, Head of Market, Havas Media Netherlands
Philippe opened with four pivotal shifts: the rise of Retail Media Networks, the need for AI readiness, stores as digital platforms, and leadership in sustainable transformation.
Klaus Smets framed Hanshow as a key enabler connecting retailers, brands, and media agencies. He emphasized that the next frontier in Retail Media is in-store, where shelves, carts, and screens form a unified media network.
“By turning physical stores into data-driven, omnichannel touchpoints, we can synchronize availability, pricing, and messaging right where decisions are made,” he noted. Klaus added that Hanshow’s all-in-one platform, combining ESLs, smart carts, and digital signages—enables intelligent, media-capable stores powered by AI, backed by strong local service, and anchored in ESG principles.
Bas Komen detailed Albert Heijn’s Retail Media Services aim to build brands and drive conversion for CPG brands, built on insights and strategic partnerships. Bart Zoetmulder emphasized Havas’s shift to a tech-first agency model, leveraging real-time shopper data and ‘Havas Forecast’ to scale personalization.
The panel concluded that retail transformation requires collaboration across media, retail, and technology anchored in the store. Hanshow’s mission is to bridge these domains and deliver actionable, data-driven in-store experiences.
Shaping the Future: Smarter, Greener, and Closer to Clients
Hanshow will continue investing in IoT, AI, and communication technologies, —ESLs, digital signage, smart carts, and robots. The company is expanding local service capabilities across Europe, the Americas, and APAC to ensure faster deployment and agile response.
Committed to ESG-aligned innovation, Hanshow aims to reduce environmental impact, and create long-term value through deeper collaboration with global tech and regional partners.
“We’re not just building technology, we’re co-designing the digital roadmap for the next era of retail with our clients,” said Shiguo Hou, CEO of Hanshow. “Innovation must empower, not isolate.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250619798164/en/
Contacts
info@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom